AU2021239084A1 - Treatment with powdered intranasal epinephrine - Google Patents
Treatment with powdered intranasal epinephrine Download PDFInfo
- Publication number
- AU2021239084A1 AU2021239084A1 AU2021239084A AU2021239084A AU2021239084A1 AU 2021239084 A1 AU2021239084 A1 AU 2021239084A1 AU 2021239084 A AU2021239084 A AU 2021239084A AU 2021239084 A AU2021239084 A AU 2021239084A AU 2021239084 A1 AU2021239084 A1 AU 2021239084A1
- Authority
- AU
- Australia
- Prior art keywords
- epinephrine
- pharmaceutical composition
- particles
- dose
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989913P | 2020-03-16 | 2020-03-16 | |
| US62/989,913 | 2020-03-16 | ||
| US17/135,528 US11400045B2 (en) | 2020-03-16 | 2020-12-28 | Treatment with powdered intranasal epinephrine |
| US17/135,528 | 2020-12-28 | ||
| PCT/IL2021/050288 WO2021186437A1 (en) | 2020-03-16 | 2021-03-16 | Treatment with powdered intranasal epinephrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021239084A1 true AU2021239084A1 (en) | 2022-10-13 |
Family
ID=77664091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021239084A Pending AU2021239084A1 (en) | 2020-03-16 | 2021-03-16 | Treatment with powdered intranasal epinephrine |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11400045B2 (https=) |
| EP (1) | EP4121005A1 (https=) |
| JP (1) | JP2023517532A (https=) |
| KR (1) | KR20220154709A (https=) |
| CN (1) | CN115279340A (https=) |
| AR (1) | AR121593A1 (https=) |
| AU (1) | AU2021239084A1 (https=) |
| BR (1) | BR112022018440A2 (https=) |
| CA (1) | CA3175130A1 (https=) |
| IL (1) | IL296268A (https=) |
| MX (1) | MX2022011464A (https=) |
| TW (1) | TW202200119A (https=) |
| WO (1) | WO2021186437A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| PT3962455T (pt) | 2020-05-18 | 2022-10-13 | Orexo Ab | Nova composição farmacêutica para entrega de fármacos |
| US12414916B2 (en) | 2021-06-10 | 2025-09-16 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| US12029709B2 (en) | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
| KR20250048076A (ko) * | 2022-08-11 | 2025-04-07 | 드 모투 코르디스 피티와이 엘티디 | 흡입형 에피네프린 제형 |
| TW202502309A (zh) * | 2023-05-31 | 2025-01-16 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物 |
| US20260108686A1 (en) | 2024-10-21 | 2026-04-23 | Belhaven BioPharma Inc. | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8337817B2 (en) * | 2006-12-26 | 2012-12-25 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
| CN102166219B (zh) * | 2010-05-25 | 2013-04-17 | 杭州天龙药业有限公司 | 一种鼻腔给药制剂及其应用 |
| US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
| MX2016002705A (es) | 2013-09-03 | 2016-09-06 | G2B Pharma Inc | Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides. |
| US20200069582A1 (en) | 2014-07-03 | 2020-03-05 | Darren Rubin | Inhalable hemodynamic agents and methods of using the same |
| CN107205938A (zh) * | 2014-12-18 | 2017-09-26 | 温德加普医疗股份有限公司 | 用于溶解或增溶治疗剂的方法和组合物 |
| US11844859B2 (en) * | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| EP3668490A4 (en) * | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
| GB2600026B (en) * | 2018-02-06 | 2022-10-12 | Aegis Therapeutics Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
-
2020
- 2020-12-28 US US17/135,528 patent/US11400045B2/en active Active
-
2021
- 2021-03-16 MX MX2022011464A patent/MX2022011464A/es unknown
- 2021-03-16 JP JP2022552858A patent/JP2023517532A/ja active Pending
- 2021-03-16 EP EP21714436.9A patent/EP4121005A1/en active Pending
- 2021-03-16 CA CA3175130A patent/CA3175130A1/en active Pending
- 2021-03-16 WO PCT/IL2021/050288 patent/WO2021186437A1/en not_active Ceased
- 2021-03-16 BR BR112022018440A patent/BR112022018440A2/pt unknown
- 2021-03-16 AR ARP210100664A patent/AR121593A1/es unknown
- 2021-03-16 KR KR1020227033697A patent/KR20220154709A/ko not_active Withdrawn
- 2021-03-16 CN CN202180020993.7A patent/CN115279340A/zh active Pending
- 2021-03-16 AU AU2021239084A patent/AU2021239084A1/en active Pending
- 2021-03-16 IL IL296268A patent/IL296268A/en unknown
- 2021-03-16 US US17/911,523 patent/US20230105615A1/en active Pending
- 2021-03-16 TW TW110109439A patent/TW202200119A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175130A1 (en) | 2021-09-23 |
| EP4121005A1 (en) | 2023-01-25 |
| TW202200119A (zh) | 2022-01-01 |
| WO2021186437A1 (en) | 2021-09-23 |
| KR20220154709A (ko) | 2022-11-22 |
| BR112022018440A2 (pt) | 2022-11-01 |
| MX2022011464A (es) | 2022-11-14 |
| US20210283050A1 (en) | 2021-09-16 |
| US11400045B2 (en) | 2022-08-02 |
| IL296268A (en) | 2022-11-01 |
| US20230105615A1 (en) | 2023-04-06 |
| AR121593A1 (es) | 2022-06-22 |
| CN115279340A (zh) | 2022-11-01 |
| JP2023517532A (ja) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11400045B2 (en) | Treatment with powdered intranasal epinephrine | |
| JP7621220B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| US11116723B2 (en) | Dry powder compositions for intranasal delivery | |
| AU2021200503B2 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| US12303472B2 (en) | Pharmaceutical device for use in intranasal administration | |
| CN105101955A (zh) | 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物 | |
| US20240358650A1 (en) | Inhalable hormone receptor agonist formulations | |
| CN110505873B (zh) | 鼻内肾上腺素制剂及治疗疾病的方法 | |
| US20140377365A1 (en) | Sustained-release formulation of rotigotine | |
| KR19990021931A (ko) | 미세구형 전분의 항편두통 조성물 | |
| KR20260016535A (ko) | 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물 | |
| Hickey | Introduction: A Guide to Treatment and Prevention of Tuberculosis Based on Principles of Dosage Form Design and Delivery | |
| HK40018410B (en) | Intranasal epinephrine formulations and methods for the treatment of disease |